Scandinavian ChemoTech

Vetiqure are expanding their partnership with Equitom, Europe's foremost equine clinic renowned for its groundbreaking advancements in equine healthcare, by establishing a Centre of Excellence for TSE.

With its distinguished reputation and status as the largest and most innovative equine clinic in Europe, Equitom has consistently pushed the boundaries of equine medicine. Vetiqure's TSE technology has been recognized by Equitom as a game-changer in the treatment of, amongst others, sarcoids, a common tumour among horses.

Following the successful integration of the vetIQure™ system into Equitom's operations, Equitom is poised to become a hub for excellence in utilising TSE technology for equine healthcare.

"Our specialists believe in the added value of Vetiqure's TSE therapy. This innovative technique wins in efficiency and user-friendliness and is a real added value for our patients. It is our shared responsibility to strive for the best possible healthcare for horses," said Dr Tom Mariën founder and CEO of Equitom. "The collaboration between Vetiqure and Equitom's specialists will lead to better insights into treatments and together we will push boundaries in the treatment of tumours in horses."

"We are proud to partner with Equitom and empower them with our TSE technology," said Mohan Frick, CEO of Scandinavian ChemoTech. "Equitom's commitment to advancing equine medicine aligns perfectly with our mission to provide innovative solutions for veterinary care. Together, we aim to set a new standard for equine healthcare."

As Equitom prepares to embark on this new chapter as a Centre of Excellence for TSE, both organisations are excited about the potential to revolutionise and transform equine healthcare and improve outcomes for horses worldwide.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.